Leqembi's best quarter since launch Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 29 July, 2026

sponsored by Medicine is a national security asset. America wins by building, not retreating. Adversary states are investing to control the biopharmaceutical capacity that national security now depends on. China already hosts 39 percent of the world's clinical trials. America cannot afford to surrender leadership of this strategic industry. But tariffs, decoupling, and blanket bans are not toughness. They are retreat. America wins by building capacity at home and with trusted allies, and by out-competing rivals instead of hiding from them. See where we stand

news Exclusive: After learning the ropes as Recursion CEO, Chris Gibson joins VC firm Dimension Capital Leqembi records best quarter since launch as Biogen raises guidance Alnylam's stock is down 30% despite a booming biotech market. Here's why

Jul 30 1:00 pm ET Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights sponsored by GUARDANT Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM

Associate Director / Director, Preclinial Development - Immunology Terray Therapeutics, Inc. Monrovia, CA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Machine Learning Researchers and Engineers D. E. Shaw Research New York, NY, USA Scientist, Drug Discovery Data for AI/ML D. E. Shaw Research New York, NY, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

A year into the tariff era, the biopharma industry has stopped bracing for impact — however manufacturing and supply chain leaders are still rewriting their plans on the fly. We’re bringing together the experts tracking what R&D logistics looks like today. Join us — find out what’s next.

ENDPOINTS PHARMA FDA reminds investors that re-evaluations don’t equal new conclusions. Just ask Capricor and Replimune •  FDA staff say Replimune's pivotal melanoma trial failed to prove RP1 works, pushing down stock FDA offers updated guidance for generics of weight loss blockbusters J&J proposes $5.5B talc settlement

in case you missed it 1. Updated: GSK reveals three-year blueprint to cut costs and propel R&D 2. Claris collects $118M to take eye drop into pivotal testing next year 3. Updated: Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism 4. News Briefing Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3 5.